Company Overview and News
KUALA LUMPUR (Sept 18): The FBM KLCI is expected trade range bound today and hover around the 1,800-point level today, given the positive domestic sentiment after Morgan Stanley last week upgraded Malaysia stocks to equal weight
GMALF 7006 9598 GMALY 4995 4715 7208 MS
KUALA LUMPUR (Sept 14): Based on corporate announcements and news flow today, companies that may be in focus on Tuesday (Sept 18) may include the following: Tropicana Corp Bhd, Latitude Tree Holdings Bhd, Versatile Creative Bhd, Vertice Bhd, Euro Holdings Bhd, Genting Malaysia Bhd, Gamuda Bhd and Pintaras Jaya Bhd.
GMALY 4995 4715 GMALF 7208 7006 BSMAF 9598 1818
SHAH ALAM (Sept 14): Pintaras Jaya Bhd is expecting half of its revenue for financial year ending June 30, 2019 (FY19) to be coming from Singapore, after venturing into the island nation by acquiring a piling company there from the family of the group’s managing director Dr Chiu Hong Keong for RM16.71 million.
Pintaras Jaya Bhd (Aug 7, RM2.69) Maintain hold with a reduced target price of RM2.46: Pintaras Jaya Bhd secured RM150 million of new contracts in the financial year ended June 30, 2018 (FY18), higher than the RM20 million to RM30 million in new contract wins in FY17. The largest contract secured in FY18 was the one for RM68.5 million to provide piling and substructure works for the Riveria Sentral office and serviced apartment.
KUALA LUMPUR (June 20): The FBM KLCI pared its gains substantially at the midday break today, tracking its regional peers as China's stock markets fell.
HLFBF APEXF PBLOF 7090 UPBMF 1082 5681 BATS 4162 1295 2089 7077 5014 9598 KLKBY 2445 3301 2216 5819 MYPRY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...